NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies

被引：42

作者：

Alyea, Edwin P. ^{[1
]}

DeAngelo, Daniel J. ^{[1
]}

Moldrem, Jeffrey ^{[2
]}

Pagel, John M. ^{[3
,4
]}

Przepiorka, Donna ^{[5
]}

Sadelin, Michel ^{[6
]}

Young, James W. ^{[6
]}

Giralt, Sergio ^{[2
]}

Bishop, Michael ^{[7
]}

Riddell, Stan ^{[3
,4
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[4] Univ Washington, Seattle, WA 98195 USA

[5] US FDA, Rockville, MD 20857 USA

[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[7] NCI, Bethesda, MD 20892 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 08期

关键词：

Allogeneic hematopoietic cell transplantation; Relapse prevention; Acute graft-versus-host disease; Immunotherapy; Resistant leukemia; CHRONIC MYELOID-LEUKEMIA; GRAFT-VERSUS-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; CYTOTOXIC T-LYMPHOCYTES; BONE-MARROW-TRANSPLANTATION; CHRONIC MYELOGENOUS LEUKEMIA; ANTIGEN-PRESENTING CELLS; TOTAL-BODY IRRADIATION; REDUCED-INTENSITY TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGENS;

D O I：

10.1016/j.bbmt.2010.05.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prevention of relapse after allogeneic hematopoietic stem cell transplantation is the most likely approach to improve survival of patients treated for hematologic malignancies. Herein we review the limits of currently available transplant therapies and the innovative strategies being developed to overcome resistance to therapy or to fill therapeutic modalities not currently available. These novel strategies include nonimmunologic therapies, such as targeted preparative regimens and posttransplant drug therapy, as well as immunologic interventions, including graft engineering, donor lymphocyte infusions, T cell engineering, vaccination, and dendritic cell-based approaches. Several aspects of the biology of the malignant cells as well as the host have been identified that obviate success of even these newer strategies. To maximize the potential for success, we recommend pursuing research to develop additional targeted therapies to be used in the preparative regimen or as maintenance posttransplant, better characterize the T cell and dendritic cells subsets involved in graft-versus-host disease and the graft-versus-leukemia/tumor effect, identify strategies for timing immunologic or nonimmunologic therapies to eliminate the noncycling cancer stem cell, identify more targets for immunotherapies, develop new vaccines that will not be limited by HLA, and develop methods to identify populations at very high risk for relapse to accelerate clinical development and avoid toxicity in patients not at risk for relapse. Biol Blood Marrow Transplant 16: 1037-1069 (2010) (C) 2010 American Society for Blood and Marrow Transplantation

引用

页码：1037 / 1069

页数：33

共 281 条

[81] Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes [J].